Cabaletta bio to participate in the td cowen 45th annual health care conference

Philadelphia, feb. 26, 2025 (globe newswire) -- cabaletta bio, inc. (nasdaq: caba), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the company will participate in a fireside chat at the td cowen 45th annual health care conference on monday, march 3, 2025, at 11:50 a.m. et in boston, ma.
COWN Ratings Summary
COWN Quant Ranking